https://scholars.lib.ntu.edu.tw/handle/123456789/592113
標題: | Topical use of systemic drugs in dermatology: A comprehensive review | 作者: | HSIEN-YI CHIU TSEN-FANG TSAI |
公開日期: | 2011 | 出版社: | Mosby Inc. | 卷: | 65 | 期: | 5 | 來源出版物: | Journal of the American Academy of Dermatology | 摘要: | Background: Topical use of systemic agents to treat cutaneous disorders is widely applied. However, there is a lack of articles summarizing the relevant literature in a systematic way. Objective: We sought to review the published literature regarding topical use of systemic drugs that were categorized according to their mode of actions. Only drugs that are not yet commercially available in a topical preparation are included. Methods: A PubMed search was performed, using as key words "topical," "extemporaneous," "compounding," and names of each generic drug, to identify all clinical reports (1966-2009). Results: Although many systemic drugs are used topically, randomized controlled trials were limited to a few agents. Limitation: Many of the reports consist only of small case series or are anecdotal in nature. As the level of evidence is limited, larger prospective trials are needed before firm conclusions can be drawn. Conclusion: Extemporaneous compounding helps physicians to individualize treatment to the patient's specific needs and to create topical preparations that are not otherwise commercially available. However, comparative effectiveness studies are needed to determine whether or not topical use of systemic therapeutics is more beneficial than existing therapies. ? 2010 by the American Academy of Dermatology, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054118230&doi=10.1016%2fj.jaad.2010.08.034&partnerID=40&md5=2776064de3bf00ce9414df56b1953a9a https://scholars.lib.ntu.edu.tw/handle/123456789/592113 |
ISSN: | 0190-9622 | DOI: | 10.1016/j.jaad.2010.08.034 | SDG/關鍵字: | acetylsalicylic acid; allopurinol; alpha interferon; bleomycin; caffeine; chlorpromazine; cidofovir; cimetidine; clobetasol propionate; clonazepam; colchicine; cycloserine; dutasteride; finasteride; granulocyte colony stimulating factor; granulocyte macrophage colony stimulating factor; griseofulvin; hydrocortisone; lidocaine; methotrexate; nonsteroid antiinflammatory agent; phenytoin; propylthiouracil; prostaglandin E2; sucralfate; testosterone; thalidomide; thiamazole; topical agent; unindexed drug; absence of side effects; acne; acne vulgaris; actinic keratosis; acute herpetic neuralgia; allergic reaction; allodynia; alopecia; analgesia; anus fissure; aphthous ulcer; application site inflammation; atopic dermatitis; burning sensation; calcinosis; condyloma acuminatum; decubitus; dermatitis; discoid lupus erythematosus; drug dosage form comparison; drug efficacy; drug mechanism; drug tolerability; erosion; erosive dermatosis; fluorouracil induced stomatitis; genital herpes; genital ulcer; hemangioma; herpes simplex; hidradenoma; human; hyperhidrosis; hyperpigmentation; immunomodulation; Kaposi sarcoma; leg ulcer; leukoplakia; lichen planus; lichen sclerosus et atrophicus; lymphomatoid papulosis; male type alopecia; mouth pain; mouth ulcer; mucosa inflammation; mucosal disease; neuralgia; periodontitis; postherpetic neuralgia; priority journal; psoriasis; psoriasis vulgaris; radiation dermatitis; randomized controlled trial (topic); review; scabies; skin defect; skin disease; skin flap survival; skin irritation; skin ulcer; stomatitis; systematic review; systemic therapy; tinea corporis; tinea pedis; tinea versicolor; ulcer; ulcerative dermatosis; unspecified side effect; uterine cervix carcinoma in situ; vasculitis; verruca vulgaris; vitiligo; wound healing |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。